HEPHAISTOS-Pharma secures a €2 million seed round
Summary
ONCO-Boost is a novel class of TLR4 immunostimulants that turn cold tumors into hot ones, increasing the efficacy of other therapies, notably immune-checkpoint inhibitors.Orsay, France, January 23rd, 2024. HEPHAISTOS-Pharma, a biotechnology company developing next generation immunotherapies against cancer, today announced that it has raised a 2 million seed round to finance GMP transfer and advance its lead candidate towards the clinic. The valuable and dedicated team developed a promising TLR4 compound that will be used systemically which will bring to the oncologists a best-in-class product for their cancer patients. We are also thankful to our historical investors and new business angels from Angels Sante, who joined the round.The proceeds from this financing round will enable HEPHAISTOS to industrialize its manufacturing process and prepare for the clinical phases, with the goal of advancing its lead candidate, ONCO-Boost, into clinical development for the treatment of solid tumors with high unmet medical needs, in particular sarcoma. Ingrid Kelly, Partner at xista science ventures, commented that \xab HEPHAISTOS has an impressive set of preclinical data, showing the high potential of their TLR4 agonist ONCO-Boost to tackle solid tumors, particularly in combination with immunotherapies such as checkpoint inhibitors.The proceeds will also be used to open a new subsidiary in Liege, Wallonia.